tazarotene has been researched along with Fifth Phacomatosis in 1 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, JY | 1 |
| Chiou, AS | 1 |
| Mackay-Wiggan, JM | 1 |
| Aszterbaum, M | 1 |
| Chanana, AM | 1 |
| Lee, W | 1 |
| Lindgren, JA | 1 |
| Raphael, MA | 1 |
| Thompson, BJ | 1 |
| Bickers, DR | 1 |
| Epstein, EH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome[NCT00489086] | Phase 2 | 36 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint used to evaluate tazarotene efficacy for BCC chemotherapy was the complete response (CR) rate, defined as the complete visible disappearance of a patient's target lesion during the the 18 months of tazarotene application and its failure to recur during the ensuing 18-months. We defined surgical removal of a target lesion as a treatment failure. The primary endpoint was assessed based on intention to treat analysis such that any subject who underwent the baseline evaluation and applied at least 1 dose of tazarotene was included in the analysis. Drop-outs were considered non-responders. A priori treatment success for tazarotene was defined as a CR rate of at least 50%, and treatment failure was defined as a CR rate of 25% or less." (NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | 2 |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
1 trial available for tazarotene and Fifth Phacomatosis
| Article | Year |
|---|---|
Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome.
Topics: Adult; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Cross-Over Studies; Dermatologic Agents; Do | 2014 |